Latest News

In this section you will find the latest Bayer Schering Pharma press releases for the United Kingdom.

If you have a particular enquiry about any of these releases then please contact us on the telephone number or e-mail address below:-

Tel: 01635 563198

E-mail: bsp-communications@bayerhealthcare.com

Natural hormone inspires new contraceptive pill

8th June 2009 

New combined oral contraceptive pill offers more choice to meet the individual needs of women today. >>more

Bayer Schering Pharma presents positive results of phase II study with Riociguat

19th May  2009 

Positive data from a phase II trial with Bayer Schering Pharma’s oral agent riociguat for the treatment of two different forms of pulmonary hypertension (PH); chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); were presented today at the American Thoracic Society (ATS) international conference in San Diego, USA. >>more

NICE Appraisal Consultation Document does not recommend funding Nexavar® ▼ (sorafenib) for advanced liver cancer patients

6th May  2009 

Patients denied chance for extra time with family and loved ones after initial refusal to fund first systemic therapy proven to extend overall survival.>>more

NICE continues to ration access to kidney cancer medicines, preventing doctors from providing the best possible treatment option for each individual

28th April 2009 

Today the National Institute for Health and Clinical Excellence (NICE) announced the Final Appraisal Determination (FAD) for Nexavar® (sorafenib), Sutent® (sunitinib), Avastin® (bevacizumab) and Torisel® (temsirolimus) in advanced kidney cancer. NICE has not recommended sorafenib, bevacizumab and temsirolimus as first line treatment option for kidney cancer. Furthermore, it does not recommend sorafenib or sunitinib for second line treatment for renal cell carcinoma (RCC) patients.>>more

First ever emergency contraception TV advert

23rd April 2009 

The first ever UK TV advertisement campaign for emergency contraceptive pill (ECP), Levonelle® One Step, launches today.>>more

NICE recommends Xarelto® (rivaroxaban) use in NHS

22nd April 2009 

Without preventative treatment, 45,000 people undergoing elective hip or knee replacement every year in England could develop a potentially fatal blood clot. NICE now recommends Xarelto® – a new, oral anticoagulant, up to 70% more effective at reducing blood clots than the current gold standard (injectable enoxaparin).>>more

Bayer Schering Pharma Announces New Distribution Arrangements in the UK

31st March 2009 

Bayer Schering Pharma (BSP), (the prescription medicines arm of Bayer HealthCare in the UK) is to distribute selected products (BSP Products) under a new reduced wholesaler model, with Alliance Healthcare (Distribution) Limited (UniChem), Phoenix Healthcare Distribution Limited and AAH Pharmaceuticals Limited, effective from 1st July 2009. >>more

The Scottish Medicines Consortium (SMC) approves NEBIDO▼® for Testosterone Deficiency Syndrome

9th March 2009 

The SMC has today accepted Nebido® (testosterone undecanoate) for use in Scotland for the treatment of hypogonadism, also known as Testosterone Deficiency Syndrome (TDS), when testosterone deficiency has been confirmed by clinical features and biochemical tests.>>more

NICE Recommends Xarelto® (rivaroxaban) use in NHS

4th March 2009 

The National Institute for Health and Clinical Excellence (NICE) has issued an initial positive opinion on the new oral anticoagulant Xarelto® for the prevention of potentially fatal blood clots after elective hip or knee replacement surgery.>>more

Bayer Schering Pharma Receives Approval to Initiate Phase III Program for Investigational Pulmonary Hypertension Therapy

18th February 2009 

Based on the positive findings of the clinical development phase II trial, Bayer Schering Pharma has received ethical approval from the Cambridgeshire 1 Research Ethics Committee in the United Kingdom to begin the phase III program for its oral agent riociguat.>>more

Font size
- 1 2 3 + Font size

click to adjust

Page tools
Search
. Advanced search







http://www.bayerscheringpharma.co.uk/scripts/pages/en/press/index.php

Copyright © Bayer Schering Pharma AG